Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

Abstract Background Trastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Evidence regarding post–T-DM1 treatments is currently lacking. We evaluated the effectiveness of post–T-DM1 drug th...

Full description

Bibliographic Details
Main Authors: Takahiro Nakayama, Tetsuhiro Yoshinami, Hiroyuki Yasojima, Nobuyoshi Kittaka, Masato Takahashi, Shoichiro Ohtani, Seung Jin Kim, Hiroyuki Kurakami, Naoko Yamamoto, Tomomi Yamada, Takehiko Takata, Norikazu Masuda
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Retrospective observational study
HER2-positive
Unresectable and/or metastatic breast cancer
KBCSG-TR 1917
T-DM1/trastuzumab emtansine
Online Access:https://doi.org/10.1186/s12885-021-08504-1

Internet

https://doi.org/10.1186/s12885-021-08504-1

Similar Items